Inflammation and cardiovascular disease role of the interleukin-1 receptor antagonist

Circulation

Volumn 117, Issue 20, 2008, Pages 2577-2579

  Fearon, William F ^a   Fearon, Douglas T ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN;

AORTA; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSLIPIDEMIA; EDITORIAL; ENDOTHELIUM; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SMOKING; CARDIOVASCULAR DISEASE; INFLAMMATION; NOTE; PATHOLOGY; PHYSIOLOGY;

CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RECOMBINANT PROTEINS;

EID: 47649109011     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.772491     Document Type: Editorial

References (23)

1. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(suppl II):II-2-II-10.
2. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
3. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996; 87:2095-2147.
4. Muruve DA, Pétrilli V, Zaiss AK, White LR, Clark SA, Ross PJ, Parks RJ, Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol. 2007;19:615- 622.
5. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:656-660.
6. Chamberlain J, Evans D, King A, Dewberry R, Dower S, Crossman D, Francis S. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am J Pathol. 2006;168:1396-1403.
7. Isoda K, Shiigai M, Ishigami N, Matsuki T, Horai R, Nishikawa K, Kusuhara M, Nishida Y, Iwakura Y, Ohsuzu F. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation. 2003;108:516-518.
8. Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M, Iwakura Y, Ohsuzu F. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2004;24:1068-1073.
9. Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M, Takayanagi T, Egashira K, Takeshita A. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo: the role of platelet-derived growth factor. J Clin Invest. 1996;97:769-776.
10. Chamberlain J, Gunn J, Francis S, Holt C, Crossman D. Temporal and spatial distribution of interleukin-1 beta in balloon injured porcine coronary arteries. Cardiovasc Res. 1999;44:156-165.
11. Morton AC, Arnold ND, Gunn J, Varcoe R, Francis SE, Dower SK, Crossman DC. Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model. Cardiovasc Res. 2005;68:493-501.
12. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996;16:1000-1006.
13. Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffery S, Kaski JC, Cumberland DC, Duff GW, Crossman DC. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation. 1999;99:861- 866.
14. Kastrati A, Koch W, Berger PB, Mehilli J, Stephenson K, Neumann FJ, von Beckerath N, Böttiger C, Duff GW, Schömig A. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol. 2000;36:2168-2173.
15. Patti G, D'Ambrosio A, Dobrina A, Dicuonzo G, Giansante C, Fiotti N, Abbate A, Guarnieri G, Di Sciascio G. Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease. J Thromb Thrombolysis. 2002;14:139-143.
16. Patti G, D'Ambrosio A, Mega S, Giorgi G, Zardi EM, Zardi DM, Dicuonzo G, Dobrina A, Di Sciascio G. Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J Am Coll Cardiol. 2004;43:35-38.
17. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-2204.
18. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P; 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-1419.
19. Waugh J, Perry CM. Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs. 2005;19:189-202.
20. Crossman DC, Morton AC, Gunn JP, Greenwood JP, Hall AS, Fox KA, Lucking AJ, Flather MD, Lees B, Foley CE. Investigation of the effect of interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (the MRC-ILA-HEART Study). Trials. 2008;9:8.
21. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos PN, Kremastinos DT. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117:2662-2669.
22. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how highgrade systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957-2963.
23. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, Yacoub MH. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation. 2001;104(suppl 1):I-308-I-313.